Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Boehringer Ingelheim
Express Scripts
Moodys
McKesson

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Voxilaprevir

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Voxilaprevir?

Voxilaprevir is an investigational drug.

There have been 13 clinical trials for Voxilaprevir. The most recent clinical trial was a Phase 2 trial, which was initiated on July 15th 2018.

The most common disease conditions in clinical trials are Hepatitis C, Infection, and Virus Diseases. The leading clinical trial sponsors are Gilead Sciences, University of Maryland, and National Institutes of Health (NIH).

There are twenty-seven US patents protecting this investigational drug and six hundred and seventy-five international patents.

Recent Clinical Trials for Voxilaprevir
TitleSponsorPhase
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV InfectionGilead SciencesPhase 3
Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)Partners in HealthPhase 4
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvirKirby InstitutePhase 4

See all Voxilaprevir clinical trials

Clinical Trial Summary for Voxilaprevir

Top disease conditions for Voxilaprevir
Top clinical trial sponsors for Voxilaprevir

See all Voxilaprevir clinical trials

US Patents for Voxilaprevir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Voxilaprevir   Start Trial Synthesis of an antiviral compound GILEAD SCIENCES, INC. (Foster City, CA)   Start Trial
Voxilaprevir   Start Trial Combination formulation of two antiviral compounds Gilead Pharmasset LLC (Foster City, CA)   Start Trial
Voxilaprevir   Start Trial Toll like receptor modulator compounds GILEAD SCIENCES, INC. (Foster City, CA)   Start Trial
Voxilaprevir   Start Trial Inhibitors of hepatitis C virus Gilead Pharmasset LLC (Foster City, CA)   Start Trial
Voxilaprevir   Start Trial Toll like receptor modulator compounds GILEAD SCIENCES, INC. (Foster City, CA)   Start Trial
Voxilaprevir   Start Trial Nucleoside phosphoramidate prodrugs Pharmasset, Inc. (Princeton, NJ)   Start Trial
Voxilaprevir   Start Trial Nucleoside phosphoramidate prodrugs Gilead Pharmasset LLC (Foster City, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Voxilaprevir

Drugname Country Document Number Estimated Expiration Related US Patent
Voxilaprevir Argentina 098959 2033-12-23   Start Trial
Voxilaprevir Australia 2014370125 2033-12-23   Start Trial
Voxilaprevir Canada 2934537 2033-12-23   Start Trial
Voxilaprevir China 105849118 2033-12-23   Start Trial
Voxilaprevir Eurasian Patent Organization 201691031 2033-12-23   Start Trial
Voxilaprevir European Patent Office 3087085 2033-12-23   Start Trial
Voxilaprevir Spain 2724460 2033-12-23   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
McKesson
AstraZeneca
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.